PROC Stock Overview
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide.
Procaps Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.15|
|52 Week High||US$11.98|
|52 Week Low||US$5.86|
|1 Month Change||-2.05%|
|3 Month Change||-23.28%|
|1 Year Change||-27.49%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-27.34%|
Recent News & Updates
Procaps Group reports Q2 results
Procaps Group press release (NASDAQ:PROC): Q2 Adj. EBITDA of $28M Revenue of $112M (+12.0% Y/Y) misses by $0.2M.
|PROC||US Pharmaceuticals||US Market|
Return vs Industry: PROC underperformed the US Pharmaceuticals industry which returned 4.2% over the past year.
Return vs Market: PROC underperformed the US Market which returned -22.1% over the past year.
|PROC Average Weekly Movement||6.5%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: PROC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: PROC's weekly volatility (6%) has been stable over the past year.
About the Company
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
Procaps Group Fundamentals Summary
|PROC fundamental statistics|
Is PROC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PROC income statement (TTM)|
|Cost of Revenue||US$173.75m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.65|
|Net Profit Margin||-17.01%|
How did PROC perform over the long term?See historical performance and comparison
Is PROC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PROC?
Other financial metrics that can be useful for relative valuation.
|What is PROC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does PROC's PS Ratio compare to its peers?
|PROC PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
VRNA Verona Pharma
SIGA SIGA Technologies
AERI Aerie Pharmaceuticals
PROC Procaps Group
Price-To-Sales vs Peers: PROC is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (7.7x).
Price to Earnings Ratio vs Industry
How does PROC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: PROC is good value based on its Price-To-Sales Ratio (1.9x) compared to the US Pharmaceuticals industry average (2.7x)
Price to Sales Ratio vs Fair Ratio
What is PROC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.9x|
|Fair PS Ratio||3.5x|
Price-To-Sales vs Fair Ratio: PROC is good value based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).
Share Price vs Fair Value
What is the Fair Price of PROC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PROC ($7.15) is trading below our estimate of fair value ($9.43)
Significantly Below Fair Value: PROC is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Procaps Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PROC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: PROC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PROC is expected to become profitable in the next 3 years.
Revenue vs Market: PROC's revenue (12.1% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: PROC's revenue (12.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PROC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Procaps Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: PROC is currently unprofitable.
Growing Profit Margin: PROC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PROC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PROC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PROC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: PROC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Procaps Group's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PROC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PROC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PROC has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PROC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable PROC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: PROC is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 79.8% per year.
Discover healthy companies
What is Procaps Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Procaps Group Dividend Yield vs Market|
|Company (Procaps Group)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Pharmaceuticals)||2.5%|
|Analyst forecast in 3 Years (Procaps Group)||n/a|
Notable Dividend: Unable to evaluate PROC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PROC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PROC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PROC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PROC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ruben Minski (70 yo)
Mr. Ruben Minski is Founded Procaps Group, S.A. in 1976 ant has been its Chief Executive Officer and serves as its Chairman. He received a Chemical Engineering degree from Northeastern University in Boston...
Experienced Management: PROC's management team is considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Procaps Group S.A.'s employee growth, exchange listings and data sources
- Name: Procaps Group S.A.
- Ticker: PROC
- Exchange: NasdaqGM
- Founded: 1977
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$806.693m
- Shares outstanding: 112.82m
- Website: https://www.procapsgroup.com
Number of Employees
- Procaps Group S.A.
- 9 Rue de Bitbourg
- Luxembourg City
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PROC||NasdaqGM (Nasdaq Global Market)||Yes||Ordinary Shares||US||USD||Dec 2019|
|9X1||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.